Oncology News

Name: ASCO Annual Meeting
Start: 2026-05-29T00:00:00-04:00
End: 2026-06-02T23:59:59-04:00
Location: McCormich Place

ASCO GI 2026: Encorafenib/Cetuximab Plus FOLFIRI Improves Response in BRAF V600E CRCJanuary 12, 2026
At the 2026 Gastrointestinal Cancers Symposium, BREAKWATER Cohort 3 delivered the clearest signal yet that encorafenib plus cetuximab can be paired with FOLFIRI (folinic acid [leucovorin], fluorouracil [5‑FU]… Read more: ASCO GI 2026: Encorafenib/Cetuximab Plus FOLFIRI Improves Response in BRAF V600E CRC
FDA Closes Out 2025 With 16 Oncology Approvals in Six WeeksJanuary 5, 2026
The US Food and Drug Administration (FDA) closed out 2025 with 16 hematology/oncology approvals in just six weeks, marking one of the most active periods of the year.… Read more: FDA Closes Out 2025 With 16 Oncology Approvals in Six Weeks
Oral Menin-Based Triplet Shows Strong Early Activity in ND AMLDecember 6, 2025
The phase II SAVE trial presented at the 2025 American Society of Hematology (ASH) Annual Meeting (Abstract 47) delivered early but compelling results from an all-oral regimen pairing… Read more: Oral Menin-Based Triplet Shows Strong Early Activity in ND AML